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At a Glance Commentary
Scientific Knowledge on the Subject:
Acidemia is a severe complication among critically ill patients. Despite being 
controversial, sodium bicarbonate is frequently used to increase blood pH. This 
treatment increases the strong ion difference (SID) by elevating sodium 
concentration, and raises blood pH. However, sodium bicarbonate administration 
can lead to several side effects including hypernatremia, hyperosmolality and 
intracellular acidosis. 
What This Study Adds to the Field:
This proof of concept study shows the feasibility, safety, and effectiveness of 
extracorporeal chloride removal through electrodialysis to correct acidemia. Plasma 
chloride reduction mimics the physiologic renal response to acidosis. Extracorporeal 
chloride removal by electrodialysis quickly corrects blood pH without altering plasma 
osmolarity and maintains its effects up to several hours following treatment 
suspension.
This article has an online data supplement, which is accessible from this issue's 
table of content online at www.atsjournals.org.
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5Abstract
Rationale: Acidemia is a severe condition among critically ill patients. Despite lack of 
evidence, sodium bicarbonate is frequently used to correct pH. However, its 
administration is burdened by several side effects. We hypothesized that the 
reduction of plasma chloride concentration could be an alternative strategy to correct 
acidemia.
Objectives: To evaluate feasibility, safety, and effectiveness of a novel strategy to 
correct acidemia through Extracorporeal Chloride Removal by Electrodialysis (CRe-
ED).
Methods: Ten swine (6 treatments, 4 controls) were sedated, mechanically 
ventilated and connected to an electrodialysis extracorporeal device capable of 
removing selectively chloride. In random order, an arterial pH of 7.15 was induced 
either through reduction of ventilation (respiratory acidosis) or through lactic acid 
infusion (metabolic acidosis). Acidosis was subsequently sustained for 12-14 hours. 
In treatment pigs, soon after reaching target acidemia, electrodialysis was started in 
order to restore pH.
Measurements and Main Results: During respiratory acidosis, electrodialysis 
reduced plasma chloride concentration by 26±5 mEq/L within 6 hours (final 
pH=7.36±0.04). Control animals exhibited incomplete and slower compensatory 
response to respiratory acidosis (final pH=7.29±0.03, p<0.001). During metabolic 
acidosis, electrodialysis reduced plasma chloride concentration by 15±3 mEq/L within 
4 hours (final pH=7.34±0.07). No effective compensatory response occurred in 
controls (final pH=7.11±0.08; p<0.001). No complications occurred. 
Conclusions: We described the first in-vivo application of an extracorporeal system 
targeted to correct severe acidemia by lowering plasma chloride concentration. The 
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6CRe-ED proved to be feasible, safe, and effective. Further studies are warranted to 
assess its performance in presence of impaired respiratory and renal functions.
Abstract word count: 248/250
Keywords: Acidosis; Electrolytes; Chloride; Extracorporeal Circulation; 
Electrodialysis
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7INTRODUCTION
Metabolic and respiratory acidosis are pathological conditions frequently occurring in 
critically ill patients, and are associated with increased morbidity and mortality (1-4). 
Cardiac arrhythmias, organ failure, suppression of the immune response, release of 
pro-inflammatory cytokines and bacterial proliferation are severe complications 
associated with acidemia (5-7).
The treatment of acidosis is primarily aimed at correction of the underlying cause. In 
case of persistent severe acidemia (blood pH<7.15), sodium bicarbonate is 
frequently administered in order to correct blood pH (6,8,9), although its efficacy to 
improve survival has been observed only in a selected subgroup of critically ill 
patients (10) and patients with sepsis (11). Indeed, intravenous infusion of sodium 
bicarbonate can cause side effects such as hypernatremia and hyperosmolarity (12). 
In addition, being bicarbonate hydrated carbon dioxide, its intravenous infusion 
causes a transient rise in plasma partial pressure of carbon dioxide, potentially 
leading to paradoxical intracellular acidosis (13). Furthermore, in respiratory acidosis 
the correction of the underlying cause may not be effectively achieved, especially 
when lung parenchyma is acutely (or chronically) responsible for the insufficient 
carbon dioxide elimination (14).
According to Stewart’s acid-base approach, the Strong Ion Difference (SID), i.e., the 
difference between the concentrations of strong cations ([Na+]+[K+]+[Ca2+]+[Mg2+]) 
and strong anions ([Cl-]+[Lac-]), is one of the three independent variables determining 
blood pH (7,15,16). Sodium bicarbonate infusion causes an increase in plasma 
sodium concentration leading to SID increase and, consequently, of pH. We 
hypothesized that the reduction of plasma chloride concentration, mimicking the 
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8physiologic renal response occurring during chronic respiratory acidosis, could be an 
alternative strategy to normalize blood pH by increasing plasma SID during 
experimental acidemia (16-18).
Many studies focused on the role of chloride in acid-base equilibrium (19,20). 
Chloride is the most represented anion in the extracellular fluid, and variations in 
chloride levels significantly affect the acid-base status (19). Hypo- or hyper-chloremia 
are frequently observed in acid-base derangements, especially in the ICU setting 
(20). Of note, the infusion of 0.9% NaCl-containing solutions is known to induce 
hyperchloremic acidosis through SID reduction (21,22). Conversely, hypochloremic 
alkalosis is a frequent consequence of loop-diuretic administration, because of 
urinary chloride loss through Na+-K+-2Cl- pump inhibition (23).
We developed an extracorporeal device to remove chloride in order to decrease its 
plasma concentration (Chloride Removal Electrodialysis, CRe-ED), thereby 
increasing SID and pH. This novel technique features an electrodialysis cell, as we 
previously described (24,25). Here we report the first in-vivo application of CRe-ED. 
In a swine randomized controlled crossover model of metabolic and respiratory 
acidosis, we tested feasibility, safety and effectiveness of this novel approach to 
correct severe acidemia.
Some of the results of these studies have been previously reported in the form of an 
abstract (26).
Methods
The study protocol was approved by the Italian Ministry of Health. Ten healthy piglets 
(24±2 kg, mean±SD) were anesthetized, surgically instrumented, mechanically 
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9ventilated (tidal volume (Vt): 10 mL/kg; respiratory rate (RR): 10 breaths per minute; 
PEEP: 5 cmH2O) and connected to an extracorporeal circuit through a double-lumen 
14Fr catheter positioned in the external jugular vein. The extracorporeal circuit 
consisted of a blood circuit, composed of two in-series hemofilters, an electrodialysis 
circuit and a circuit for lactic acid infusion (acid infusion circuit), connected to the first 
and the second hemofilter, respectively (Figure 1 and online data supplement). 
Anticoagulation was performed with continuous intravenous heparin infusion.
Study design
Six piglets were assigned to the CRe-ED treatment (treatment group) and four were 
controls (control group) (Figure 2). Regardless of treatment allocation, each swine 
randomly underwent both respiratory and metabolic acidosis (crossover 
randomization).
At baseline, respiratory rate was adjusted in order to achieve an arterial pH between 
7.38 and 7.42. Thereafter, pH was lowered to reach a target of 7.15±0.02 through 
either a decrease in minute ventilation by respiratory rate reduction (respiratory 
acidosis), or by a continuous infusion of 1.5 M lactic acid into the acid infusion circuit 
(metabolic acidosis).
In the treatment group, once the target pH was reached, CRe-ED was started and 
continued until normalization of arterial pH. Thereafter, CRe-ED was stopped and 
animals were monitored for 8 hours. In contrast, in the control group, CRe-ED was 
not applied, and, after induction of acidosis, animals were monitored for a total period 
comparable with the CRe-ED duration plus 8-hr monitoring period after CRe-ED 
treatment (14 hours of respiratory acidosis and 12 hours of metabolic acidosis). 
Arterial pCO2 (±3 mmHg) and lactate (±1 mEq/L) were kept constant throughout all 
Page 9 of 70  AJRCCM Articles in Press. Published on 25-September-2019 as 10.1164/rccm.201903-0538OC 
 Copyright © 2019 by the American Thoracic Society 
10
the experiments until the end of observation period, by modulating respiratory rate 
and lactic acid infusion, respectively.
Before the second phase of the assigned acidosis, plasma chloride concentrations 
were restored to baseline values (±2 mEq/L) by the infusion of 1.5 M hydrochloric 
acid through the acid infusion circuit (re-chloration phase).
Data collection
At the end of each step (i.e., baseline, start and end of CRe-ED treatment, 4h and 
end (8h) of observation period), every hour during CRe-ED treatment and every two 
hours during the control observation period, we collected hemodynamic and 
ventilator parameters; laboratory biomarkers, and blood gas analyses and 
electrolytes from arterial line and extracorporeal circuit; urinary output, pH and 
urinary electrolytes (27); glomerular filtration rate.
Statistical Analysis
Data are presented as mean±standard deviation unless otherwise specified. 
Differences among groups were tested by a 2-way analysis of variance for repeated 
measurements over time. Multiple comparisons analyses were tested among 
different time points versus baseline, start and end of CRe-ED treatment using 
Dunnet’s test. A p-value<0.05 (two-tailed) was deemed statistically significant.
Please refer to the online data supplement for detailed methods.
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During respiratory acidosis, targeted pH was achieved by decreasing minute 
ventilation from 4.0±0.8 L/min to 1.8±0.2 (p<0.001) in the treatment group, and from 
3.7±0.7 to 1.6±0.2 L/min (p<0.001) in the control group (Table 1). An increase in 
pCO2 from 45±6 mmHg to 91±12 mmHg (p<0.001) and from 49±4 mmHg to 95±6 
mmHg (p<0.001) was recorded in the treatment and control groups, respectively. 
Subsequently, pCO2 was kept constant during the whole experiment in both groups 
(Figure 3A).
In the treatment group, after the application of CRe-ED, plasma chloride 
concentration decreased from 103.7±3.4 mEq/L to 78.2±8.0 mEq/L (p<0.001) 
(Figure 3B), thereby leading to an increase in plasma SID from 41.4±4.4 mEq/L to 
64.2±9.5 mEq/L, (p<0.001), and an increase in HCO3– from 30.7±3.6 mEq/L to 
54.3±6.6 mEq/L, (p<0.001) (Table 1). As plasma chloride concentration decreased 
and SID increased, arterial pH increased from 7.16±0.01 to 7.40±0.01 (p<0.001). 
Correction of pH during CRe-ED treatment was achieved in 333±59 minutes (range, 
255-430 minutes) (Figure 3C). During the 8-h observation period, pH slightly 
decreased from 7.40±0.01 to 7.36±0.04 (p<0.001), as plasma chloride concentration 
increased from 78.2±8.0 mEq/L to 84.8±4.6 mEq/L (p<0.001) (Figure 3B,C).
In control animals, we observed a slower compensatory response to respiratory 
acidosis: SID and HCO3– progressively increased from 41.7±3.5 to 53.3±3.9 mEq/L 
(acidosis induction to end of observation, p<0.001), and from 32.6±2.8 to 43.6±2.3 
mEq/L (p<0.001), respectively (Table 1). Accordingly, over the whole 14 hours of 
respiratory acidosis, pH increased in the control group from 7.16±0.01 to 7.29±0.03, 
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though up to a lower level as compared to the treatment group (p<0.001) (Figure 
3C).
Table 1 summarizes respiratory, hemodynamic, plasma electrolytes, acid-base 
status and renal function changes over time among the groups during respiratory 
acidosis. Plasma biochemistry and respiratory variables in both groups, as well as 
electrolytes concentrations in the treatment group along the withdrawal port of the 
extracorporeal circuit are reported in Table E1-E4.
Urinary response 
At acidosis induction, urinary pH (pHu) decreased in the treatment (acidosis induction 
versus baseline, 4.9±0.3 versus 5.8±0.5, p=0.013) and control group (4.7±0.2 versus 
5.5±0.5, p=0.118), although only in the treatment group pH reduction reached 
statistical significance (Figure 4A). No significant change of urinary chloride and 
ammonium concentration was observed in both treatment and control groups (Table 
2 and Figure 4 A-C).
In the treatment group, during CRe-ED treatment, urinary chloride concentration 
significantly decreased from 179.3±29.2 to 34.3±14.1 mEq/L (p<0.001) and urinary 
anion gap (AG) increased accordingly from -79.6±32.6 to 79.9±65.3 (p<0.001) (Table 
2). Consequently, pHu increased from 4.9±0.3 up to 6.9±1.0 (p<0.001) and remained 
stable during the 8h observation (Figure 4A, Table 2). Overall, the restoration of 
baseline blood pH required the removal of 392±65 mEq of chloride ions, of which 
336±54 mEq were removed by CRe-ED and 56±37 mEq by the renal system, mainly 
excreted during the acidosis induction phase (Figure 4B).
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In the control group, a total of 248±65 mEq of chloride were removed by the kidneys 
during the entire 14-h period of respiratory acidosis, causing constantly negative 
values of urinary anion gap (Table 2), and leading to a decrease in plasma chloride 
concentration from 105±4 (acidosis induction) to 92±5 mEq/L (end of observation) 
(p<0.001) (Figure 4B). Of note, after the induction of respiratory acidosis, creatinine 
clearance increased from 69.1±13.7 (baseline) to a maximum value of 141.4±29.9 
mL/min (p=0.002) (Table 1).
Metabolic acidosis
Metabolic acidosis was induced and maintained by infusing 2.2±0.4 mL/kg/h of 40% 
lactic acid (3.5±1.3 mmol/min) on the acid infusion circuit. From baseline to the end 
of lactic acidosis induction, plasma lactate concentration increased from 0.6±0.2 to 
13.1±1.5 mmol/L (p<0.001) in the treatment group and from 0.6±0.2 to 12.9±1.5 
mmol/L (p<0.001) in the control group (Figure 5A). As a consequence, plasma SID 
decreased from 38.7±5.4 to 26.5±2.7 mEq/L in the treatment group (p<0.001) and 
from 42.6±6.1 to 28.6±5.2 mEq/L in the control group (p=0.001), while HCO3- 
decreased from 28.5±5 to 16.0±2.4 mEq/L in the treatment group (p<0.001), and 
from 29.1±1.4 to 16.6±1.4 mEq/L in the control group (p<0.001) (Table 3). Targeted 
arterial pH was similarly achieved in both treatment and control groups (7.16±0.02 
and 7.16±0.02 respectively, p<0.001 versus baseline) (Figure 5B).
In the treatment group, plasma chloride was removed by CRe-ED, and its 
concentration decreased from 106±4 to 91±6 mEq/L, from the beginning to the end of 
CRe-ED treatment, respectively (p<0.001) (Figure 5C). Consequently, plasma SID 
and HCO3- significantly increased (Table 3) and arterial pH returned to baseline after 
199±43 minutes of CRe-ED treatment (range, 135-255 minutes) (Figure 5C). Of 
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note, arterial pH remained stable from the end of the CRe-ED treatment to the end of 
the observation period (Figure 5C). In contrast, after infusion of lactic acid in the 
control group, no spontaneous correction of acidosis was observed (Figures 5C).
Table 3 summarizes respiratory, hemodynamic, plasma electrolytes, acid-base 
status and renal function changes over time among the groups during lactic 
acidosis. Plasma biochemistry and respiratory variables in both groups, as well as 
electrolyte concentrations in the treatment group along the withdrawal port of the 
extracorporeal circuit are reported in Table E5-E8.
Urinary response 
During acidosis, in both treatment and control groups, urinary pH (pHu) decreased 
(Figure 6A) while urinary ammonium and chloride concentration increased only in 
the control group (Table 2 and Figures 6 A-C).
In the treatment group, during CRe-ED treatment, pHu remained significantly lower 
compared to baseline (from 5.0±0.4 versus 5.7±0.7, p=0.016), did not differ 
compared to acidosis induction (versus 4.7±0.3, p=0.569) and remained stable 
during the 8h of observation (Figure 6A and Table 2). Furthermore, urinary chloride 
concentration decreased from 85.8±51.6 (acidosis induction) to 34.5±16.7 mEq/L 
(end of treatment) (p=0.160) (Figure 6B) and urinary AG increased accordingly from 
-1.4±54.5 to 46.8±45.4 (p=0.123), although these differences did not reach statistical 
significance (Table 2). Overall, normal arterial pH was restored by the removal of 
185±56 mEq of chloride, of which 159±55 mEq were removed by CRe-ED and 26±9 
mEq by urinary output, mainly excreted during the acidosis induction phase (Figure 
6B).
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In the control group, cumulative urinary chloride excretion was 77±46 mEq (Figure 
6B).
In all the treated animals by CRe-ED, no treatment was withdrawn due to the 
development of complications, including cardiac arrhythmias, pulmonary 
hypertension, or visible signs of hemolysis.
Discussion
In this experimental proof of concept study, we were able to reduce plasma chloride 
concentration in vivo through an extracorporeal device characterized by an 
electrodialysis cell (CRe-ED), aimed at selective chloride removal. The removal of 
plasma chloride rapidly corrected the acidemia regardless of the respiratory or 
metabolic origin of the acidosis. Indeed, during respiratory acidosis, six hours of 
CRe-ED treatment increased arterial pH from 7.16 to 7.40 by decreasing chloride 
concentration from 104 to 78 mEq/L. During metabolic acidosis, less than four hours 
of CRe-ED treatment were necessary to increase arterial pH from 7.16 to 7.40, 
through a reduction of chloride from 106 to 92 mEq/L. Within the same time frame, 
six and four hours, control swine subjected to comparable acidosis were able to 
increase arterial pH up to 7.29±0.03 only during respiratory acidosis while no 
modifications of pH were recorded during metabolic acidosis.  
This is the first in vivo application of an extracorporeal electrodialytic device aimed at 
restoring physiologic pH during severe acidosis through selective plasma chloride 
removal. Chloride is the main anion in the extracellular fluid, and it has a key role in 
the regulation of acid-base equilibrium. As an example, because of SID reduction, 
hyperchloremia is a well-known cause of metabolic acidosis, as reported after 
administration of normal saline (19,20). Conversely, gastrointestinal, renal or sweat 
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chloride loss may lead to hypochloremia, which, by increasing SID, causes metabolic 
alkalosis (28). Hypochloremia is likewise found in hypercapnic patients suffering from 
chronic obstructive pulmonary disease as a response to chronic respiratory acidosis 
(29). Selective binding and removal of hydrochloric acid from the gastrointestinal tract 
has been recently introduced as a novel treatment for chronic metabolic acidosis in 
patients suffering from chronic kidney disease. In a recently published randomized 
clinical trial, veverimer was able to achieve in 12 weeks a least squares mean 
change from baseline of blood bicarbonate of +4.4 mEq/L compared to +1.8 mEq/L 
of the placebo group (30). 
In our experimental setting, investigating acute acidosis, CRe-ED normalized pH 
from 7.15 to 7.40 extremely rapidly. This was achieved through an average reduction 
of about 26 and 15 mEq/L in plasma chloride concentration, leading to an increase in 
blood bicarbonate of about 24 and 12 mEq/L, during respiratory and metabolic 
acidosis, respectively. According to Stewart’s model, these decreases in chloride 
concentrations lead to an equivalent increase in SID, provided that strong cation 
concentrations remain constant. Sodium bicarbonate is a known therapeutic option to 
treat metabolic acidosis (6,12). However, if identical pH corrections were performed 
by administering sodium bicarbonate, a similar increase in SID would have been 
achieved at the cost of a marked increase of sodium concentration, with an increase 
in plasma osmolarity, and the consequent water shifts from the intracellular toward 
the extracellular fluid compartment. Indeed, sodium bicarbonate is burdened by side 
effects, such as increased plasma osmolarity, intracellular acidosis, and even risk of 
myelinolysis, when rapidly administered (6,12,13,31).
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As mentioned above, the rationale of CRe-ED arises from the physiological response 
of the renal system to acidosis, and, in parallel, from the physico-chemical approach 
to acid-base by Peter Stewart. According to traditional knowledge of renal 
physiology, the kidney reacts to acid load by enhancing net acid excretion (mainly 
through an increased NH4+ excretion), and HCO3– reabsorption / regeneration (32). 
The net result will be an increase in plasma HCO3– concentration. However, due to 
electroneutrality, an increased HCO3– concentration will inevitably be associated with 
a reduction of strong anions (Cl–), provided that osmolality remains constant. In 
control animals, during respiratory acidosis urinary pH decreased, paralleled by a 
significant increase in urinary NH4+ excretion. Such modifications were, however, 
also associated with a parallel increase in urinary Cl– excretion, likely due to an 
increase in Cl– voltage-dependent channel secretion to preserve electroneutrality 
after the increased activity of distal H+-ATPase pumps (33-34). Indeed, CRe-ED 
treatment switched-off such compensatory mechanism, possibly as a consequence 
of a very rapid reduction of the available Cl– content in the peritubular capillary, and 
of the increase in urinary pH. During metabolic acidosis, we observed a similar, 
although markedly blunted, course of urinary Cl– and NH4+ concentration, while in 
contrast, urinary pH remains acidotic also during CRe-ED treatment. Although a full 
understanding of this mechanism cannot be achieved, we may speculate that a 
significant urinary excretion of another strong anion, i.e., lactate, was present, 
thereby limiting urinary pH correction despite the selective plasma Cl– removal and 
the associated progressive pH correction.
In order to selectively reduce the concentration of plasma chloride while maintaining 
a constant plasma sodium concentration, we have modified the electrodialysis circuit 
previously used to enhance extracorporeal CO2 removal (23,25). Treatment of 
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metabolic acidosis by conventional continuous renal replacement therapy (CRRT) 
would have partially increased blood pH by removing fixed acids with little, if any, 
change in plasma chloride concentration (35-37), depending on the composition of 
the dialytic bath. Treatment of respiratory acidosis by conventional CRRT might be 
potentially effective at increasing blood pH through a chloride reduction exclusively in 
conjunction with the use of replacement fluids with low or zero chloride concentration. 
Unfortunately, the use of such fluids are not commercially available today. However, 
CRRT would have also changed plasma sodium concentration towards the 
concentration of the replacement solution. Therefore, the final effect on blood pH and 
SID would have resulted by both the modifications of chloride and sodium, thus 
making it impossible to assess the sole effect of chloride reduction. Indeed, CRe-ED 
provided an effective treatment of acidemia through a selective and controlled 
plasma chloride removal.
After pH correction by CRe-ED, plasma chloride concentration was lowered to 91±6 
and 78±8 mEq/L during metabolic and respiratory acidosis, respectively. We 
recorded no major adverse events of either hemodynamic, blood gas or biochemical 
nature. Furthermore, no visible signs of haemolysis were detected despite the 
concentration of plasma chloride in the post-filter blood was as low as 85±7 mEq/L 
and 71±8 mEq/L after metabolic and respiratory acidosis correction, respectively, 
with a chloride shift across the first hemofilter of 5.0±2.1 mEq/L and 7.4±1.9 mEq/L, 
and an associated pH of 7.290.09 and 7.370.02, respectively. However, despite 
maintaining a steady plasma osmolarity, we do not know to what extent chloride 
removal can be forced before causing harmful side effects in vivo, and this issue will 
require future investigation. Indeed, both hyper- and hypochloremia have been 
associated with adverse outcomes (38-40), when associated with pathological 
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conditions. Hyperchloremia was associated with immune activation, clotting 
impairment, decreased splanchnic perfusion, renal vasoconstriction and the 
consequent reduction in glomerular filtration (19,20,41). In the recent SALT 
randomized trial, ICU patients exposed to higher volumes of saline infusion – which 
was associated with higher levels of serum chloride – presented a higher incidence 
of the composite outcome of major adverse kidney events at 30 day follow up, 
compared to larger volumes of balanced crystalloid infusions. This finding suggested 
a potential dose-response relationship between intravenous fluid-related 
hyperchloremia and outcome (42). On the other hand, hypochloremia is considered a 
marker of illness severity (43), even though no specific threshold appears to be 
independently associated to unfavourable outcomes and a definite causal connection 
is lacking. To the best of our knowledge, no complications attributable to low chloride 
levels have been reported even at very low levels of chloremia (44).
As a secondary aim, our study was also designed to evaluate the hypothesis that the 
increment in pH achieved with a single CRe-ED treatment, would have been 
sustained even after the suspension of the treatment despite maintaining the 
underlying acidosis. This hypothesis has been partially refuted by the experimental 
data observed. Indeed, shortly following CRe-ED suspension during both respiratory 
and metabolic acidosis, pH slightly dropped to 7.36 and 7.33 at 4h, but it remained 
subsequently stable until the end of the observation period (7.36 and 7.34). The drop 
in pH was associated to an increase of plasma chloride concentration by about 7 and 
4 mEq/L during the observation period of the respiratory and metabolic acidosis, 
respectively. Indeed, such increase in chloremia was not associated with a renal-
induced chloride retaining state occurring after the achievement of very low level of 
hypochloremia, since urinary excretion of chloride remained active even after the end 
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of CRe-ED treatment (see Figure 4c and 6c). We may speculate that plasma chloride 
increase may be at least partially associated with a chloride shift back into the 
plasma from other connecting fluid compartments, most likely from red blood cells 
(45,46), during a very rapid, and likely non-physiological reduction of plasma chloride 
concentration. In addition, intravenous administration of fluid maintenance during the 
observation period, which included chloride, may have played a role. Further data are 
warranted to evaluate the potential stability of low levels of hypochloremia over a 
longer period of time. 
The application of CRe-ED, although still as a prototype in a pilot animal study, 
opens up the possibility of promising future applications, that may have an important 
impact in clinical settings. 
First, CRe-ED may represent the only possibility of rapidly correcting acidosis when 
the renal system is failing. In the present study, we applied CRe-ED to healthy 
animals. However, patients admitted to ICU, often develop impaired renal function, a 
further hurdle which affects the physiologic response to acidosis (47). It is therefore 
conceivable that critically ill patients, such as patients with septic shock, acute 
respiratory failure, and other pathological processes, may benefit from CRe-ED even 
at greater extent.
Second, CRe-ED may represent a unique method facilitating the tolerance of 
hypercapnia, when related to the necessity of reducing minute ventilation during 
mechanical ventilation, such as during ARDS. In the present experimental setting of 
respiratory acidosis, chloride removal of about 400 mEq allowed to reduce minute 
ventilation down to 50% while keeping a constant pCO2 (as high as about 90 mmHg). 
Extracorporeal chloride removal could be applied to patients with respiratory failure 
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(i.e. ARDS patients) to buffer acidemia generated by permissive hypercapnia (7,48). 
This could be beneficial in severe ARDS patients, enabling a low tidal volume 
protective mechanical ventilation without the drawback of acidemia consequent to 
permissive hypercapnia induction. Furthermore, preclinical evidence supports the 
association of severe hypercapnic acidosis with immunosuppression, bacterial 
proliferation in sepsis and increased injury in lung cells (49-51). Caples SM et al. 
reported that buffering hypercapnic acidosis can protect alveolar cells and enhance 
the repair of wounded cells after exposure to injurious ventilation (51). The 
application of CRe-ED in ARDS patients could easily support even the use of ultra-
low tidal volume ventilation (52).
Third, CRe-ED might be suitable as an intermittent treatment to enhance the 
tolerance of chronic hypercapnia, such as in the case of patients with chronic 
respiratory failure. Patients with chronic obstructive pulmonary disease often develop 
hypochloremia, which compensates for hypercapnia and a high plasma HCO3– 
concentration. However, this compensation is hardly achievable in the presence of 
concomitant chronic kidney disease, and may be limited by the maximal chloride 
excretive capability of the renal system. In this scenario, patients with end-stage 
respiratory failure are not only challenged by hypoxemia, but they are also unable to 
handle further minimal loads of CO2. We speculate that the application of an 
intermittent chloride removal may increase the tolerance to higher levels of CO2, thus 
extending the life span and improving the quality of life for those patients. 
Fourth, therapeutic modulation of plasma chloride concentration could have some 
advantages in the treatment of acid-base and hydro-electrolytic imbalances. Chloride 
removal proved to be effective in increasing blood pH, and, in case of hyperchloremic 
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acidosis, such as following administration of conspicuous amounts of normal saline, it 
would also effectively treat the cause of acidosis. On the opposite side, the 
administration of highly concentrated hydrochloric acid through a dialysis circuit, as 
performed during the re-chloration phases, could be a feasible and safe alternative to 
the historical treatment of systemic alkalosis based on direct infusion of diluted 
hydrochloric acid (53,54).
Our study presents also some limitations. First, this experimental investigation was a 
proof-of-concept study in healthy animals. Therefore, no information about the effect 
of normalization of respiratory or metabolic acidosis in critically ill patients, such as 
during respiratory failure or renal impairment can be determined. Second, we did not 
evaluate higher safety limits of chloride removal, both in terms of total amount of 
chloride to be removed and velocity of chloride shift from plasma. Third, we cannot 
establish the time of chloride removal by CRe-ED in humans, but we assume it may 
be longer relative to the time needed to remove chloride in this preclinical 
investigation model, based on estimated total body chloride. Fourth, during the 
metabolic acidosis experiment, compensatory respiratory response to acidosis was 
not permitted, as arterial PCO2 was maintained constant from baseline until the end 
of the observation period. 
In conclusion, we documented the first in vivo application of an extracorporeal 
system targeted to correction of severe acidemia by lowering plasma concentration 
of chloride. In two experimental models of metabolic and respiratory acidosis, CRe-
ED proved to be superior in normalizing arterial pH compared to the physiological 
compensatory response in healthy controls. Further studies are warranted to access 
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the feasibility and safety profile of CRe-ED, especially with regard of the amount and 
the shift velocity of plasma chloride modulation.
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Figure legends
Figure 1. Schematic of extracorporeal circuit and electrodialysis (ED) unit. In 
the blood circuit, blood flowed (150 and 200 mL/min, during respiratory and metabolic 
acidosis experiments, respectively) through two serially connected hemofilters. In the 
ED circuit, ultrafiltrate was generated by the first hemofilter (30 mL/min), flowed 
through a calcium filter, the ED base chamber, a membrane lung (ML), and after a 
safety filter it was reinfused between the two hemofilters. To prevent calcium 
precipitation inside the ED cell, 30 mL/min of ultrafiltrate was recirculated from the 
outlet of the ED base chamber prior to the calcium filter, in order to alkalize the 
ultrafiltrate and to allow calcium precipitation and entrapment into the calcium filter. A 
gas mixture of CO2 was delivered into the gas inlet port of the ML to target the pH of 
ultrafiltration fluid after the ML between 7.50 and 8.50. Finally, 30 mL/min of normal 
saline solution was driven towards the ED acid chamber and then wasted. The ED 
circuit was powered only during the chloride removal ED (CRe-ED) treatment. In the 
acid infusion circuit, outlet and inlet hemodiafiltration ports of the second hemofilter 
were connected to create a closed loop circuit, with the dialysate flowing 
countercurrent to the blood flow. Lactic acid 1.5 M and hydrochloric acid 1.5 M were 
infused into the acid infusion circuit during the experimental phases of the metabolic 
acidosis and re-chloration phases, respectively. Nine different withdrawal ports were 
arranged in the circuit: 1 blood pre-filter, 2 blood post-filter, 3 ultrafiltrated fluid, 4 ED 
base inlet pre-filter, 5 ED base inlet post-filter, 6 ED base outlet pre-ML, 7 ED base 
outlet post-ML, 8 ED acid inlet and 9 ED acid outlet (Figure 1). Enlarged figure in 
Figure 1 represents the details of the ED unit. The ED unit was customized with two 
bipolar membranes (bpm) and one anionic membrane (am) creating four chambers: 
anode, acid chamber, base chamber and cathode. Electric current forces the 
Page 30 of 70 AJRCCM Articles in Press. Published on 25-September-2019 as 10.1164/rccm.201903-0538OC 
 Copyright © 2019 by the American Thoracic Society 
31
movement of anions (mainly chloride) from the base to the acid chamber (Figure 1, 
online data supplement). In red, the blood circuit; in light and dark green, the ED 
circuit; in light blue, the acid infusion circuit.
Figure 2. Study design. First, the animals were allocated in two groups, the 
Treatment group (Chloride Removal Electrodialysis (CRe-ED) group), on the left, and 
the Control group, on the right. Regardless of treatment assignment, each piglet was 
subjected to two randomly ordered experiments (metabolic and respiratory acidosis). 
In the CRe-ED group, both experiments consisted of: 1) a baseline step; 2) an 
acidosis induction phase (either metabolic with infusion of lactic acid by the acid 
infusion circuit or respiratory by reducing the respiratory rate); 3) the restoration of 
the baseline arterial pH (pHa) by CRe-ED treatment; and 4) finally 8 hours of 
observation (Observation Treatment). In control subjects, CRe-ED was not applied 
and thus, after the 1) baseline and 2) acidosis induction phase, 3) the physiological 
response to acidemia was observed for 12 and 14 hours during metabolic and 
respiratory acidosis, respectively (Observation Control). Before starting the second 
randomized experiment, plasma chloride was restored to the baseline value (±2 
mEq/L) of the first experiment.
Figure 3. Induction of respiratory acidosis and effects of CRe-ED treatment on 
blood acid-base balance. Black circles with dashed line represent the treatment 
group. White squares with dotted line represent the control group. Time 0 
corresponds to the start of the CRe-ED or of the observation in the treatment and 
control group, respectively. Data are reported as mean±SD. p-value of difference 
between groups is reported by a 2-way ANOVA for repeated measurements over 
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time. * p<0.05 vs baseline step in treatment group; ‡ p<0.05 vs baseline step in 
control group.
Figure 4. Urinary electrolytes and pH changes over time after induction of 
respiratory acidosis and CRe-ED treatment. Black circles with dashed line 
represent the treatment group. White squares with dotted line represent the control 
group. Red circles with dashed-dotted line represent the total amount of chloride 
removed in the treatment group by CRe-ED and urine output. Time 0 corresponds to 
the start of the CRe-ED or of the observation in the treatment and control group, 
respectively. Data are reported as mean±SD. p-value of difference between groups is 
reported by a 2-way ANOVA for repeated measurements over time. * p<0.05 vs 
baseline step in treatment group; ‡ p<0.05 vs baseline step in control group.
Figure 5. Induction of metabolic lactic acidosis and effects of CRe-ED 
treatment on blood acid-base balance.  Black circles with dashed line represent 
the treatment group. White squares with dotted line represent the control group. Time 
0 corresponds to the start of the CRe-ED or of the observation in the treatment and 
control group, respectively. Data are reported as mean±SD. p-value of difference 
between groups is reported by a 2-way ANOVA for repeated measurements over 
time. * p<0.05 vs baseline step in treatment group; ‡ p<0.05 vs baseline step in 
control group. 
Figure 6. Urinary electrolytes and pH changes over time after induction of 
metabolic lactic acidosis and CRe-ED treatment. Black circles with dashed line 
represent the treatment group. White squares with dotted line represent the control 
group. Red circles with dashed-dotted line represent the total amount of chloride 
removed in the treatment group by CRe-ED and urine output. Time 0 corresponds to 
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the start of the CRe-ED or of the observation in the treatment and control group, 
respectively. Data are reported as mean±SD. p-value of difference between groups is 
reported by a 2-way ANOVA for repeated measurements over time. * p<0.05 vs 
baseline step in treatment group; ‡ p<0.05 vs baseline step in control group.
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Table 1. Physiological variables and electrolytes changes during and after induction of respiratory acidosis
CRe-ED treatment Observation
Baseline


























Vt/kg [mL] 10.1 ± 0.2 10.0 ± 0.3 10.2 ± 0.4 10.2 ± 0.6 10.0 ± 0.4 9.8 ± 0.4 9.8 ± 0.5 9.8 ± 0.5 9.7 ± 0.5 10.3 ± 1.1 0.806




4.0 ± 0.8 3.7 ± 0.7 1.8 ± 0.2* 1.6 ± 0.2‡ 1.9 ± 0.2* 1.9 ± 0.3‡ 1.9 ± 0.3* 1.8 ± 0.3‡ 1.9 ± 0.4* 1.9 ± 0.3‡ 0.648
Electrolytes and 
acid-base status
Na+ [mmol/L] 136.7 ± 2.6 137.3 ± 3.0 137.0 ± 2.5 138.3 ± 4.1 136.0 ± 3.2 137.5 ± 4.4 137.0 ± 3.2 136.5 ± 5.5 136.8 ± 3.3 137.8 ± 5.6 0.716
K+ [mmol/L] 3.9 ± 0.3 4.0 ± 0.7 4.1 ± 0.4 4 ± 0.6 3.3 ± 0.2* 3.8 ± 0.3 3.4 ± 0.3 3.7 ± 0.3 3.4 ± 0.5 3.7 ± 0.3 0.259
Ca 2+ [mmol/L] 1.4 ± 0.1 1.3 ± 0.2 1.4 ± 0.1 1.3 ± 0.2 1.2 ± 0.1* 1.2 ± 0.1 1.1 ± 0.1* 1.2 ± 0.1 1.1 ± 0.1* 1.3 ± 0.1 0.718
Mg2+ [mg/dL] 1.8 ± 0.3 1.9 ± 0.2 1.9 ± 0.4 2.1 ± 0.4 1.4 ± 0.3* 1.8 ± 0.2 1.7 ± 0.3 2.0 ± 0.3 1.8 ± 0.2 1.8 ± 0.2 0.297
HCO3- [mEq/L] 27.3 ± 3.6 30.6 ± 2.2 30.7 ± 3.6* 32.6 ± 2.8 54.3 ± 6.6* 37.4 ± 1.5‡ 49.5 ± 4.9* 40.6 ± 2.2‡ 49.3 ± 2.8* 43.6 ± 2.3‡ 0.043
Acidosis 
Induction
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BE [mmol/L] 2.4 ± 3.4 5.5 ± 2.0 2.8 ± 3.4 4.1 ± 2.3 27.3 ± 5.9* 9.8 ± 1.3‡ 22.3 ± 4.4* 13.1 ± 2.1‡ 22.1 ± 2.3* 16.2 ± 2.1‡ 0.020
Lactate [mmol/L] 0.7 ± 0.2 0.6 ± 0.4 0.3 ± 0.1* 0.4 ± 0.2‡ 0.5 ± 0.1* 0.3 ± 0.1‡ 0.4 ± 0.1* 0.3 ± 0.1‡ 0.5 ± 0.1* 0.3 ± 0.1‡ 0.839
SID [mEq/L] 38.8 ± 4.5 41.0 ± 2.4 41.4 ± 4.4 41.7 ± 3.5 64.2 ± 9.5* 47.6 ± 3.1 60.6 ± 6.6* 49.1 ± 4.3 58.6 ± 4.2* 53.3 ± 3.9‡ < 0.001
Hemodynamics
HR [bpm] 107 ± 25 116 ± 36 120 ± 21 137 ± 34 123 ± 16 131 ± 26 127 ± 25 126 ± 16 121 ± 28 112 ± 22 0.717
MAP [mmHg] 96 ± 22 111 ± 18 102 ± 17 98 ± 17 86 ± 13 93 ± 10 96 ± 8 91 ± 13 87 ± 10 88 ± 11 0.679
CVP [mmHg] 8 ± 3 12 ± 2 8 ± 3 11 ± 2 7 ± 3 10 ± 3 8 ± 2 11 ± 3 9 ± 2 11 ± 4 0.093
PMAP [mmHg] 26 ± 4 30 ± 9 34 ± 7* 36 ± 7 27 ± 5 31 ± 4 29 ± 3 31 ± 3 28 ± 4 32 ± 3 0.230
WP [mmHg] 10 ± 3 14 ± 4 10 ± 4 13 ± 2 9 ± 3 12 ± 4 10 ± 2 13 ± 3 11 ± 2 13 ± 4 0.146
CO [L/min] 3.4 ± 0.6 3.5 ± 0.3 4.0 ± 0.5 4.6 ± 1.1 3.1 ± 0.8 4.7 ± 0.8 3.8 ± 0.9 5.0 ± 1.2‡ 3.8 ± 0.5 4.2 ± 0.6 0.055
Renal function
Urea [mg/dL] 14.7 ± 3.2 13.3 ± 7.5 14.8 ± 4.0 14.0 ± 8.1 20.2 ± 5.2 17.8 ± 8.7 23.3 ± 6.0* 22.8 ± 5.0‡ 23.5 ± 5.4* 19.5 ± 8.4 0.565
Creatinine 




57.9 ± 17.0 69.1 ± 13.7 104.3 ± 57.7* 108.4 ± 26.7 81.0 ± 21.2 141.4 ± 29.9
‡ 64.2 ± 23.6 103.1 ± 4.4 80.7 ± 33.2 109.6 ± 35.6 0.060
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Data are reported as mean±SD. p-value of difference between groups is reported by a 2-way ANOVA for repeated measurements 
over time. * p<0.05 vs baseline step in treatment group; ‡ p<0.05 vs baseline step in control group.
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Na+U [mEq/L] 48.2 ± 44.7 67.0 ± 54.8 61.1 ± 37.1 72.1 ± 39.5 76.4 ± 61.9 115.8 ± 34.3 74.6 ± 30.6 105.9 ± 76.7 49.0 ± 36.0 88.0 ± 27.6 0.122
K+U [mEq/L] 30.1 ± 19.6 48.5 ± 38.0 38.7 ± 5.3 45.8 ± 41.9 37.9 ± 16.4 42.1 ± 24.2 31.3 ± 8.7 41.5 ± 29.4 29.9 ± 14.9 30.7 ± 22.5 0.527
Cl-U [mEq/L] 127.2 ± 87.2 151.2 ± 86.0 179.3 ± 29.2 133.9 ± 110.4 34.3 ± 14.1* 168.7 ± 129.9 54.0 ± 31.8* 186.5 ± 126.3 60.3 ± 51.6 156.8 ± 114.0 0.159
AGu [mEq/L] -48.9 ± 36.9 -35.6 ± 33.4 -79.6 ± 32.6 -16.0 ± 109.2 79.9 ± 65.3* -10.8 ± 132.2 52.0 ± 54.9* -39.1 ± 116.7 18.6 ± 62.0 -38.2 ± 93.9 0.399
Metabolic 
acidosis
Na+U [mEq/L] 37.5 ± 37.7 100.5 ± 98.4 47.0 ± 28.9 70.4 ± 70.6 32.3 ± 26.4 43.6 ± 43.6‡ 28.3 ± 26.3 42.7 ± 30.6‡ 25.2 ± 22.1 32.1 ± 39.0‡ 0.364
K+U [mEq/L] 33.2 ± 21.6 22.7 ± 3.4 37.4 ± 11.2 32.2 ± 10.5 49.0 ± 25.5 28.0 ± 19.2 30.6 ± 13.2 20.4 ± 11.7 27.1 ± 16.9 14.9 ± 10.1 0.162
Cl-U [mEq/L] 102.1 ± 72.6 185.7 ± 67.8 85.8 ± 51.6 63.4 ± 47.9‡ 34.5 ± 16.7* 49.3 ± 32.1‡ 34.8 ± 25.5* 93.9 ± 64.7‡ 35.3 ± 29.0* 91.1 ± 62.0‡ 0.077
AGu [mEq/L] -31.5 ± 39.8 -62.5 ± 53.3 -1.4 ± 54.5 39.2 ± 31.9‡ 46.8 ± 45.4* 22.3 ± 45.5‡ 24.1 ± 36.6 -30.9 ± 103.3 17.0 ± 34.4 -44.1 ± 79.2 0.347
Acidosis 
Induction
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Data are reported as mean±SD. p-value of difference between groups is reported by a 2-way ANOVA for repeated measurements 
over time. * p<0.05 vs baseline step in treatment group; ‡ p<0.05 vs baseline step in control group.
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Vt/kg [mL] 10.2 ± 0.2 9.7 ± 0.4 10.2 ± 0.2 9.5 ± 0.9 10.2 ± 0.2 9.5 ± 0.9 10.1 ± 0.2 9.4 ± 0.9 10.0 ± 0.3 9.6 ± 1.0 0.112
RR 




3.7 ± 0.7 3.7 ± 0.5 5.3 ± 0.8* 5.3 ± 0.9‡ 5.1 ± 0.6* 5.6 ± 1.0‡ 5.2 ± 0.8* 5.7 ± 0.9‡ 5.2 ± 1.3* 6.1 ± 1.0‡ 0.505




Na+ [mmol/L] 135.8 ± 2.6 138.0 ± 1.4 137.3 ± 2.1 136.8 ± 1.3 136.0 ± 2.4 133.0 ± 5.9‡ 136.5 ± 2.4 135.3 ± 3.0 136.5 ± 2.9 134.3 ± 3.6 0.476
K+ [mmol/L] 4.1 ± 0.6 3.7 ± 0.4 3.6 ± 0.4* 3.5 ± 0.3 3.0 ± 0.5* 3.4 ± 0.2 2.6 ± 0.4* 3.3 ± 0.3 2.7 ± 0.4* 3.5 ± 0.8 0.352
Ca2+ [mmol/L] 1.4 ± 0.1 1.4 ± 0.0 1.5 ± 0.1* 1.5 ± 0.1 1.3 ± 0.1 1.4 ± 0.1 1.3 ± 0.1 1.4 ± 0.0 1.3 ± 0.1 1.4 ± 0.0 0.049
Mg2+ [mg/dL] 1.8 ± 0.1 2.1 ± 0.4 1.8 ± 0.1 2.1 ± 0.4 1.4 ± 0.1* 1.9 ± 0.2 1.7 ± 0.1 2.1 ± 0.4 1.7 ± 0.2 2.0 ± 0.3 0.020
Acidosis 
Induction
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BE [mmol/L] 0.9 ± 5.4 4.1 ± 1.3 -10.2 ± 3.6* -10.5 ± 1.6‡ 3.2 ± 4.4 -11.7 ± 3.1‡ -1.1 ± 3.5 -12.5 ± 4.4‡ -0.4 ± 6.3 -13.4 ± 3.4‡ 0.007
HCO3- [mEq/L] 28.5 ± 5.0 29.1 ± 1.4 16.0 ± 2.4* 16.6 ± 1.4‡ 28.2 ± 4.7 15.6 ± 2.5‡ 24.3 ± 3.6* 15.0 ± 3.2‡ 25.0 ± 6.2* 14.2 ± 2.6‡ 0.023
SID [mEq/L] 38.7 ± 5.4 42.6 ± 6.1 26.5 ± 2.7* 28.6 ± 5.2‡ 38.6 ± 4.7 22.1 ± 8.9‡ 35.2 ± 3.4 25.0 ± 1.7‡ 35.6 ± 5.8 23.0 ± 3.2‡ <0.001
Hemodynamics
HR [bpm] 109 ± 15 103 ± 20 115 ± 18 96 ± 18 111 ± 19 115 ± 24 101 ± 14 119 ± 26 103 ± 14 127 ± 26 0.700
MAP [mmHg] 98 ± 23 99 ± 20 98 ± 13 100 ± 16 87 ± 6 93 ± 12 89 ± 11 88 ± 9 86 ± 12 90 ± 9 0.687
CVP [mmHg] 8 ± 2 9 ± 3 8 ± 2 10 ± 3 7 ± 2 10 ± 3 7 ± 2 9 ± 3 7 ± 3 10 ± 3 0.214
PMAP [mmHg] 27 ± 4 24 ± 4 32 ± 4 34 ± 6 26 ± 4 37 ± 9‡ 30 ± 5 30 ± 8 28 ± 5 36 ± 11‡ 0.248
WP [mmHg] 10 ± 1 12 ± 4 10 ± 2 12 ± 4 9 ± 2 11 ± 4 10 ± 3 12 ± 5 10 ± 2 13 ± 4 0.304
CO [L/min] 3.3 ± 0.4 3.4 ± 0.6 4.2 ± 0.3* 3.4 ± 0.3 3.2 ± 0.3 3.8 ± 0.4 3.7 ± 0.4 3.9 ± 0.1 3.5 ± 0.2 3.8 ± 0.1 0.573
Renal function
Urea [mg/dL] 18.0 ± 7.0 15.3 ± 6.4 16.3 ± 4.3 16.5 ± 8.2 15.7 ± 3.4 15.0 ± 7.5 16.8 ± 4.2 16.3 ± 4.7 17.3 ± 6.1 14.5 ± 4.4 0.684
Creatinine 




77.4 ± 28.2 112.4 ± 40.6 60.3 ± 27.7 83.3 ± 31.4 64.1 ± 16.2 140.8 ± 66.9 79.2 ± 25.2 84.0 ± 12.2 71.0 ± 27.0 96.9 ± 15.0 0.023
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Data are reported as mean±SD. p-value of difference between groups is reported by a 2-way ANOVA for repeated measurements 
over time. * p<0.05 vs baseline step in treatment group; ‡ p<0.05 vs baseline step in control group.
Page 41 of 70  AJRCCM Articles in Press. Published on 25-September-2019 as 10.1164/rccm.201903-0538OC 
 Copyright © 2019 by the American Thoracic Society 
Figure 1
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Figure 4
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3Methods
Animal Preparation and Management
The study was conducted within the animal research facility at the Fondazione 
IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan. The study protocol was 
approved by the Institutional Animal Care Committee, and the experiments 
conducted according to Italian National Regulations. After a 12-hour fasting period, 
ten healthy female piglets (weight 24±2 kg) were sedated with an intramuscular 
injection of medetomidine (0.03 mg/kg) (Domitor, Orion corporation, Espoo, Finland) 
and tiletamine-zolazepam (4 mg/kg) (Zoletil, Virbac Srl, Milan, Italy). After 
catheterization of an ear vein, anesthesia was provided by continuous intravenous 
infusion of propofol (Diprivan, AstraZeneca, Basiglio, Milan, Italy) 10-15 mg/kg/h and 
medetomidine 3-6 mcg/kg/h. Analgesia was assured by intravenous administration of 
tramadol 50 mg every 12 hours. Thereafter, a surgical tracheostomy was performed 
and an endotracheal tube (diameter 7 mm) was secured in place. Once muscle 
paralysis was accomplished by intravenous administration of pancuronium-bromide 
(priming dose of 0.2 mg/Kg followed by a continuous infusion at a rate of 0.25 
mg/kg/h), mechanical ventilation was started. The ventilator (Datex-Ohmeda Inc., 
General Electrics, Madison, WI, US) was set in volume controlled mode, with tidal 
volume of 10 mL/Kg, inspiratory to expiratory time ratio of 1:2, positive end expiratory 
pressure (PEEP) of 4 cmH2O, inspiratory fraction of oxygen (FiO2) of 40% and 
respiratory rate to obtain an arterial pH (pHa) of 7.40 ± 0.02.
To monitor arterial and venous hemodynamics and to collect blood samples for 
laboratory analyses, left carotid artery and left internal jugular vein were surgically 
isolated and cannulated with an arterial catheter (5 Fr Seldicath, Prodimed, 
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4Plastimed Division, Le Plessis Bouchard, France) and a central venous catheter (7 
Fr, 3 lumen, Arrow, Reading, PA, US), respectively. To monitor pulmonary 
hemodynamics and to collect blood samples for laboratory analyses, a pulmonary 
arterial catheter (5 Fr, 4 lumen, 75cm, Edwards Lifesciences, Irvine, Canada) was 
inserted in the left internal jugular. To secure vascular access for the veno-venous 
extracorporeal circuit, a double-lumen hemodialysis catheter was surgically placed in 
the right internal jugular vein (12 Fr, 15 cm, Arrow, Reading, PA, US). Finally, 
cistostomy was performed and a Foley catheter (12 Ch Willy Rush AG, Kernen; 
Germany) was positioned into the bladder, to monitor urinary output and to collect 
urinary samples for electrolytes analyses.
Peripheral oxygen saturation (SpO2), systemic and pulmonary arterial pressures, 
central venous pressure, urinary output, EKG, and core temperature were 
continuously monitored (SC 8000 MDLC, Siemens, Munich, Germany). Cardiac 
output measure was obtained by 5 mL of 5% dextrose bolus at room temperature 
into the central venous port of the pulmonary artery catheter (Vigilance, Edwards 
Lifesciences) within 3 seconds. Cardiac output was averaged after 3 measurements 
that were within 15% of each other. End-tidal carbon dioxide partial pressure 
(ETCO2) was measured by a mainstream capnograph with an integrated airflow 
probe (CO2SMO, Novametrix - Philips Respironics, Murrysville, PA, US). Expired 
minute volume and airways pressure were measured by the mechanical ventilator 
(Datex-Ohmeda Inc., General Electrics). During the entire experiment, Ringer’s 
Lactate solution was infused at the rate of 4 mL/kg/h, unless otherwise specified.
Antibiotic prophylaxis was accomplished administering 1 g of ceftriaxone (Fidato, 
Fidia Spa, Padova, Italy) every 12 hour. 
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5Following a parenteral injection of 150 IU/kg of unfractionated heparin (UFH), the 
animals were connected to a custom-made veno-venous extracorporeal circuit via 
the double lumen hemodialysis catheter. A continuous infusion of UFH was then 
titrated, with a target of activated clotting time (ACT) (Hemocron, ITC, Edison, NJ, 
US) between 200-250 seconds. During the whole experiment, an average UFH 
infusion of 52866±22514 IU/day was required to obtain an ACT of 235±56 seconds.
At the end of the experiment, all the animals were euthanized, while still under deep 
anesthesia, through an injection of 40 mEq of potassium chloride.
Extracorporeal Circuit
The extracorporeal circuit was composed by a blood circuit, an electrodialysis (ED) 
circuit and an acid circuit (see Figure 1). The blood circuit included a drainage limb, 
a roller pump (RS-7800 Minipump, Renal Systems, Minneapolis, MN, US), two 
serially connected hemofilters (FX60, surface area 1.4 m2, Fresenius Medical Care, 
Bad Homburg, Germany), and a re-infusion limb. Blood flow was kept constant at 
150 and 200 mL/min in the experimental phase of respiratory acidosis and metabolic 
acidosis, respectively.
In the ED circuit, 30 mL/min of ultrafiltration fluid was generated from the first 
hemofilter by means of a peristaltic pump (PD 5206, Heidolph Instruments, 
Schwabach, Germany). This ultrafiltration fluid was diverted firstly towards a filter 
(calcium filter, FX50, Fresenius Medical Care), secondly into the ED base chamber, 
then through a pediatric membrane lung (ML) (Quadrox-iD Pediatric, Maquet 
Cardiopulmonary, Rastatt, Germany) and finally re-infused in the blood circuit among 
the two hemofilters. The gas inlet of the ML was connected to an air/CO2 gas 
blender. To avoid potential embolization, we positioned an additional filter (safety 
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6filter, FX50, Fresenius Medical Care) prior to the reinfusion of the ultrafiltrate fluid 
into the blood stream. An additional pump (PD 5206, Heidolph) was utilized to 
generate a re-circulating 30 mL/min of ultrafiltrate fluid from the outlet of the ED base 
chamber prior to the calcium filter. Finally, 30 mL/min of normal saline solution was 
driven by a roller pump (PD 5206, Heidolph) towards the ED acid chamber and then 
wasted.
In the acid circuit, outlet and inlet hemodiafiltrate ports of the second hemofilter were 
connected to create a closed loop circuit, so that the dialisate fluid flowed 
countercurrent to the blood flow at the rate of 600 mL/min by means of a peristaltic 
pump (PD 5206). Lactic acid 1.5 mol/L (Sigma-Aldrich, St. Louis, MO, US) or 
chloride acid 1.5 mol/L (Honeywell-Fluka, Morris Plains, NJ, US) was infused into the 
acid circuit during the experimental phases of the metabolic acidosis and re-
chloration, respectively. All circuit tubing was standard 1/4 or 3/16 inches (inner 
diameter). Nine different withdrawal ports were arranged in the circuit for strict 
monitoring: 1 blood pre-filter, 2 blood post-filter, 3 ultrafiltrated fluid, 4 ED base inlet 
pre-filter, 5 ED base inlet post-filter, 6 ED base outlet pre-ML, 7 ED base outlet post-
ML, 8 ED acid inlet and 9 ED acid outlet (see Figure 1). The ED unit was connected 
to a laboratory direct current (DC) power supply unit (EA-PS 3032-20B, EA Elektro 
Automatik, Munich, Germany) set to deliver a constant current output of 4 Ampere, 
maximum 20 Volt.
Electrodialysis
ED is an electrochemical process that utilizes the driving force of an electrical field to 
move ions from one solution to another one by ion-exchange membranes (E1). The 
ED unit (PCCell ED 200-OEM, PCCell GmbH, Heusweiler, Germany) (see Figure 1) 
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7is composed of a customized four-chamber cell. Three membranes were aligned 
from the anode to the cathode: 1. a bipolar membrane (BPM); 2. an anionic 
membrane (AM), and 3. another BPM. By the separation of the three membranes 
within the ED cell, four compartments were created : anode, acid chamber, base 
chamber, and cathode. The anode compartment was immersed in a solution of 
sodium sulfate (300 mOsm/L), named the anolyte, and the cathode compartment 
was in a standard saline solution (0.9 %) called catholyte. Flow was continuous into 
the anolyte and catholyte compartments and was driven by two peristaltic pumps, 
respectively, into two closed loop circuits. An exit port was placed at the top of the 2 
compartements to allow the removal of the gases produced into the cell (i.e. O2 and 
H2). An ion current was generated through the ED cell by featuring an electric field 
transversally to the fluid flow. Among the acid and base cell, the AM rectified the 
charge carriers to only negative ions. Furthermore, the two BPMs prevented 
electrolyte exchanges between the catholyte and anolyte. Contemporarely, the 
process of spontaneous water dissociation offered the necessary ion production to 
mantain the current flux inside the membranes, By peristaltic pumps, fluids flowed 
continuously in the “acid” and “base” chambers. Anions transitioned from the solution 
in the "base" chamber to the solution in the "acid” chamber through the anionic 
membrane, by means of electricity. The anion flux was kept constant by the external 
power supply, as operated at a constant current. Electrical current and ion transfer 
were related by the specific ion valence (v), I=v*1/(e*nA): “e” is the numerical value 
of the electron charge and nA is Avogadro’s number (1 Ampère corresponds to 
0.622 mEq/min, in case of monovalent ions). A single ion species transfer depends 
on its concentration times its electrophoretic mobility. As Cl- is the most represented 
anion in plasmatic water, the solution in the acid chamber mostly incorporates Cl- 
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8ions. The combination of Cl- ion with H+ ions supplied by the BPM results in an acidic 
output solution. On the contrary, in the "base" chamber, OH- ions are formed by 
hydrolysis in order to replace the loss of negative charges (i.e. Cl-); therefore, the exit 
solution is alkaline.
At the time of the development of this technique, we reported the presence calcium 
crystals precipitation as the alkaline pH of the base chamber, which blocked the 
upcoming flow. To counteract this, we conceived a technique to prevent the 
precipitation of calcium inside the ED unit. Before the base chamber, we recirculated 
a portion of the alkaline solution exiting the base chamber itself. This led to 
controlled calcium precipitation before the ED unit and to the entrapment of the 
calcium crystals into the calcium filter placed before the base chamber. As a direct 
consequence, the concentration of calcium in the solution entering the base chamber 
was remarkably reduced. This prevented the damage of the ED unit by the calcium 
precipitation into the base chamber. As last, a safety filter was positioned 
downstream of the base chamber. This prevented that any residual of calcium 
crystals could enter the bloodstream.
Experimental design
Ten healthy female piglets (weight 24±2 kg) were studied. Six subjects were 
assigned to treatment (i.e. chloride removal by ED, CRe-ED) and four to control (i.e. 
no treatment) (see Figure 2). Regardless of treatment assignment, the subjects 
underwent two randomly ordered experiments: called metabolic acidosis and 
respiratory acidosis. Briefly, each of these experiments was composed of:
1. a baseline step, to collect baseline data;
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reduction of minute ventilation, and achieving target acidosis (i.e. pH 
7.15±0.02);
3. correction of acidosis by CRe-ED, and thereby measuring the time necessary 
to pH correction; and finally, one hour after switching off CRe-ED system,
4. 8 hours of observation.
At the end of each step (i.e., baseline, start and end of CRe-ED treatment, 4h and 
end (8h) of observation period), every hour during CRe-ED treatment and every two 
hours during the control observation period, we collected the following data:
1) hemodynamic and ventilator parameters;
2) gas blood analyses, electrolytes plasma concentrations and laboratory 
analyses from blood samples obtained from the carotid artery, pulmonary 
artery and from the extracorporeal circuit; 
3) urinary output, pH and urinary electrolytes (24); 
4) glomerular filtration rate, which was estimated according to the following 
formula: (urinary creatinine*urine output)/(plasma creatinine) / (minutes) = 
mL/min.
In control subjects, ED was not applied, and thus the physiologic correction of 
acidosis was observed for 12 and 14 hours during metabolic and respiratory 
acidosis, respectively.
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During the metabolic acidosis experiment, lactic acid was continuously infused in the 
acid circuit in both groups. Starting from the baseline step with an pHa of 7.40±0.02 
and maintaining arterial pCO2 (pCO2a) constant (value of baseline step ±3 mmHg), 
the infusion of lactic acid was titrated to achieve a pH value of 7.15±0.02 (acidosis 
target step). After achieving the acidosis target step until the end of the experiment, 
lactic acid infusion was set to maintain the arterial value of lactic acid as the same 
value reached at the acidosis target step (±1.0 mEq/L). Then, in the treatment group 
during CRe-ED treatment, all peristaltic pumps of the ED circuit and power supply 
unit of the ED were on, and the gas mixture of CO2 was delivered to the gas inlet 
port of ML to target the pH of ultrafiltration fluid at the ED base outlet post-ML port 
between 7.50-8.50. The CRe-ED system worked continuously until the restoration of 
an pHa 7.40 ± 0.02 and, after that, it was turned off. Finally, one hour after the end of 
the CRe-ED treatment step, 8-hour observation period (CRe-ED observation step) 
started. PCO2a was maintained equal to (± 3 mmHg) the pCO2a at baseline step and 
lactic acid was infused to maintain an arterial lactate levels equal to (±1 mEq/L) the 
arterial lactate levels during the acidosis target step. In the control group, after the 
acidosis target step, 12-hour observation period (control observation step) started. 
PCO2a was maintained equal to (± 3 mmHg) the pCO2a at baseline and lactic acid 
was infused to maintain an arterial lactate levels equal to (±1 mEq/L) the arterial 
lactate levels during the acidosis target step. During the experimental phase of 
metabolic acidosis, ringer lactate infusion was reduced of the same volume of the 
infused volume of lactic acid.
In both groups, during the respiratory acidosis experiment, starting with a baseline 
pHa of 7.40±0.02, the tidal volume was maintained constant at 10 mL/Kg and the 
respiratory rate was reduced to achieve an pHa of 7.15±0.02 (acidosis target step). 
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After achieving the acidosis target step until the end of the experiment, the PEEP 
was set to 7 cmH2O and FiO2 was increased to keep SpO2 above 98%, in order to 
avoid hypoxia determined by hypoventilation. 
During the respiratory acidosis experiment, after achieving acidosis target pHa, the 
arterial pCO2 was maintained equal to (± 3 mmHg) the pCO2a reached during the 
acidosis target step, by changing the respiratory rate. Then, in the treatment group 
during CRe-ED treatment step, all the peristaltic pumps of the ED circuit and power 
supply unit of the ED were maintained on, and the gas mixture of CO2 was inflated 
into the gas inlet port of ML to target the pH of ultrafiltration fluid at the ED base 
outlet post-ML port between 7.50-8.50. The CRe-ED system worked continuously 
until the restoration of an pHa of 7.40 ± 0.02 and after that it was interrupted. Finally, 
one hour after the end of the CRe-ED treatment, 8-hour observation period (CRe-ED 
observation step) started. PCO2a was maintained equal to (± 3 mmHg) the pCO2a 
during the acidosis target step. In the control group after the acidosis target step, a 
12-hour observation period (control observation step) started. PCO2a was 
maintained equal to (± 3 mmHg) the pCO2a during the acidosis target step.
Since each animal was subjected to both experiments, after the end of the first 
randomized experiment, the arterial chloride level was restored as the same value 
(±2 mEq/L) as during the baseline step of the first randomized experiment, by 
chloridric acid infusion into the acid circuit.
In both experiment, at the end of baseline step and acidosis target step, every hour 
during CRe-ED treatment step and every two hour during the CRe-ED observation 
step and control observation step, hemodynamics (i.e. heart rate, mean arterial 
pressure, mean pulmonary arterial pressure, pulmonary capillary wedge pressure, 
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central venous pressure, cardiac output, core temperature and urinary output), 
ventilatory parameters (i.e. minute ventilation, respiratory rate, tidal volume, peak 
pressure, plateau pressure, PEEP and inspiratory oxygen fraction), peripheral 
oxygen saturation (SpO2) and end tidal CO2 (EtCO2) were recorded. During the same 
timepoints, blood was withdrawn for blood gas analyses (ABL 800 gas analyzer; 
Radiometer, Copenhagen, Denmark) from the carotid and the pulmonary artery. 
Of note, bicarbonate concentration [HCO3-] was calculated for each sample by 
applying known values for the solubility of CO2 in plasma (S = 0.0307 
mmol/(L·mmHg)) and the negative logarithm of the first apparent equilibrium 
dissociation constant of carbonic acid (pK’1 = 6.120), according to the following 
formula:
[HCO3-] = S · PCO2 · 10 (pH – pK’1)
where PCO2 = partial pressure of carbon dioxide (expressed in mmHg) and 
measured with the point-of-care blood gas analyzer and pH = pH measured with the 
point-of-care blood gas analyzer.
Furthermore, the serum strong ion difference (SID) and the urinary anion gap (AG) 
have been calculated as follows:
Serum SID (mEq/L)= (Na+ mEq/L)+(K+ mEq/L)+(Ca++*2 mEq/L)+(Mg mg/dL 
*10/24.3*2)-(Cl- mEq/L+Lactate- mEq/L)
Urinary AG (mEq/L)=(Na+ mEq/L)+(K+ mEq/L)-(Cl- mEq/L)
Every hour during and at the end of the CRe-ED treatment step, blood was collected 
along the blood circuit from the blood pre-filter port and blood post-filter port. 
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Similarly, the ultrafiltrated fluid was withdrawn along the ED circuit from the 
ultrafiltration fluid port and the ED base outlet post-ML port for gas analyses (ABL 
800 gas analyzer; Radiometer). Furthermore, the pH of every port of the ED circuit 
was measured simultaneously (HI9026, Hanna Instruments, San Benedetto del 
Tronto, Italy). Electrolytes (sodium, potassium, chloride, calcium, and magnesium) 
were measured in all blood or ultrafiltrate samples. Specifically, ionized calcium of 
blood samples was measured by a gas analyzer (ABL 800 gas analyzer; 
Radiometer. Sodium, potassium, chloride, totalcalcium and magnesium of all 
samples were measured by laboratory testing (ADVIA Chemistry, Siemens, 
Healthcare Diagnostics Inc., Tarrytown, NY, US). To prevent damage of the pH 
meter instruments, all ultrafiltrate samples with a pH greater than 8.0 were 
tonometered to obtain a pH between 7.0-8.0 by gaseous CO2.
Urinary output, urinary pH and urinary electrolytes (sodium, potassium and chloride) 
and urinary ammonium were measured by the urinary analyzer KING (collaboration 
of Orvim and Kardia, Milan, Italy) and synchronized with blood data collection during 
both experiments.
Before starting and at the end of each step, blood was sampled to measure 
complete laboratory chemistry (hemoglobin, platelet count, serum electrolytes, urea, 
creatinine, urea, alanine aminotransferase, aspartate aminotransferase, lactate 
dehydrogenase, gamma-glutamyl transferase, total bilirubin, albumin (ADVIA 
Chemistry).
During the experimental phases with the ED on, calcium gluconate (10%) was 
continuously infused (average infusion rate=23±13 mL/h) to maintain an arterial 
ionized calcium concentration greater than 1.0 mmol/L.
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Statistical Analysis
Data are presented as mean ± standard deviation unless otherwise specified. To test 
the hypothesis that CRe-ED treatment (exposure variable) may correct blood pH 
after induction of respiratory or metabolic acidosis (outcome variable), variation in 
continuous physiological variables and electrolyte concentrations over time was 
compared using a 2-way analysis of variance (ANOVA) for repeated measurements 
(2-way ANOVA-RM over time) testing the difference among groups (treatment 
versus control group). Multiple comparisons analyses were tested among different 
time points in each group versus baseline, start and end of CRe-ED treatment using 
Dunnet’s test. A p-value<0.05 (two-tailed) was deemed statistically significant. 
Statistical analyses were performed using STATA-14/MP (StataCorp LP, College 
Station, TX, USA), GraphPad Prism 7a (GraphPad Software, San Diego, CA, USA) 
and Microsoft Excel for Mac 2017, Version 15.32.
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Tables 


























[mg/dL] 122±33 125±37 129±12 130±58 91±32* 103±35 98±17 123±41 0.563
AST [IU/L] 28±7 77±99 24±6 61±79 27±6 52±47 38±14 46±27 0.263
ALT [IU/L] 38±9† 56±12 39±9 54±11 37±9 52±12 38±11 52±8 0.037
Gamma-




0.05±0.01 0.17±0.21 0.04±0.01 0.10±0.07 0.07±0.03 0.10±0.06 0.05±0.02 0.11±0.08 0.093
Albumin 
[g/dL] 2.6±0.7 2.8±0.5 2.6±0.7 2.7±0.6 2.5±0.6 2.5±0.4 2.3±0.4* 2.4±0.5 0.706
Phosphat




9.7±1.5 9.8±1.8 9.4±1.1 9.2±1.3 9.2±1.1 8.9±1.3 8.7±1.4 9.3±1.2 0.447
Magnesiu
m [mg/dL] 1.9±0.3 1.9 ±0.2 1.9±0.4 2.1±0.4 1.5±0.3* 1.8±0.2 1.7±0.2 1.8±0.2 0.387
LDH [IU/L] 518±132 643±112 538±146 618±100 498±162 573±59‡ 505±126 536±29‡ 0.408
Hb [g/dL] 7.2±1.7 7.8±1.7 8.2±1.5* 7.7±2.0 7.4±1.8 7.4±2.2 7.1±1.9 6.0±1.9‡ 0.850
Platelets 
[109/L] 210±117 260±115 223±133 276±154 173±82 288±178 173±99 201±151 0.461
* p<0.05 vs baseline step in treatment group; ‡ p<0.05 vs baseline step in control group. p-value of difference between groups 
with a 2-way ANOVA for repeated measurements. AST=Aspartate-Aminotransferase; IU=international unit; ALT=alanine 
amino-transferase; Gamma-GT=Gamma-Glutamyl-Transferase; LDH=Lactate Dehydrogenase; Hb=hemoglobin.
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Table E2. Respiratory variables before and after induction of respiratory acidosis
CRe-ED treatment Observation
Baseline





















T°C 37.5±1.0 37.8±1.5 38.0±1.0 38.3± 0.1 37.9±1.0 38.2±0.4 38.2±1.2 38.2±0.6 0.730
PEEP, 
cmH2O
5.0±1.4 4.8±1.0 6.0±1.3* 5.5±1.3 6.3±0.8* 5.5±1.3 6.7±1.0* 5.5±1.3 0.352
FiO2, % 46±5 48±5 47±5 55±10 47±5 58±15 47±5 61±17‡ 0.044
PaO2, 
mmHg 194±34 187±41 116±19* 167±54 147±26* 164±43 144±40* 168±62 0.274
MAP, 
cmH2O












2.4±0.7 2.1±0.5 1.0±0.2* 0.9±0.0‡ 1.0±0.2* 1.2±0.2‡ 1.0±0.2* 1.0±0.3‡ 0.984
* p<0.05 vs baseline step in treatment group; ‡ p<0.05 vs baseline step in control group. p-value of difference between groups 
with a 2-way ANOVA for repeated measurements.  FiO2=inspired fraction of oxygen; MAP=mean airway pressure; 
PEEP=positive end expiratory pressure.
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Table E3. Change of pH, pCO2 and electrolytes at the end of CRe-ED treatment in 
the blood pre-filter and blood-post-filter withdrawal port along the extracorporeal 
circuit after induction of respiratory acidosis.
1-blood pre-filter 2-blood post-filter












pH 7.19±0.02 7.34±0.01* 7.27±0.03 7.37±0.02*
pCO2 [mmHg] 102.4±16.8 105.3±13.6 106.8±11.4 112.9±11.8
pO2 [mmHg] 52.0±2.8 43.9±2.2* 45.5±9.8 40.0±7.3*
FiO2, % 42±2 43±3 42±2 43±3
HCO3- [mEq/L] 38.9±3.8 55.3±7.2* 48.8±6.8 63.0±7.0*
Lactate [mEq/L] 0.6±0.1 0.8±0.2* 0.5±0.1 0.8±0.2*
Na+ [mEq/L] 136±3 136±4 136.2±3.4 136.4±4.0
K+ [mEq/L] 4.0±0.4 3.3±0.1* 4.0±0.4 3.4±0.1*
Cl- [mEq/L] 97±5 77±8* 88±7 71±8*
Ca++ (mmol/L) 1.3±0.0 1.2±0.1* 0.9±0.1 0.9±0.0
Total Calcium 
[mg/dL] 9.7±0.3 10.4±0.9 7.2±0.9 7.9±0.8*
Phosphate 
[mg/dL] 9.9±1.3 9.6±1.7 8.2±1.3 8.0±1.7
Magnesium 
[mg/dL] 1.7±0.3 1.5±0.4 1.4±0.3 1.4±0.3
* p < 0.05 vs 1 hour ED treatment same withdrawal port by paired t-test.
Electrolytes were all measured by gas analysis (ABL 800 gas analyzer; Radiometer), except for total Calcium, phosphate and 
magnesium that were measured by laboratory testing (ADVIA Chemistry, Siemens).
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Table E4. Change of pH and electrolytes at the end of CRe-ED treatment in the different withdrawal ports along the 
extracorporeal circuit after induction of respiratory acidosis.
* p < 0.05 vs 1 hour ED treatment same withdrawal port by paired t-test.
PH of all fluids were measured with a dedicated pH-meter (HI9026, Hanna Instruments), while electrolytes were all measured by laboratory testing (ADVIA Chemistry, Siemens).
3 Ultrafiltrated fluid
4 ED base inlet 
pre-filter
5 ED base inlet 
post-filter
6 ED base outlet 
pre-ML
7 ED base outlet 
post-ML












































pH 7.49±0.13 7.63±0.11* 10.14±0.48 9.92±0.52* 10.14±0.39 9.91±0.56* 11.93±0.83 11.47±1.03* 7.98±0.53 8.01±0.14 6.34±2.14 6.08±1.99 2.37±1.72 2.36±1.47
Na+ [mEq/L] 145±1 142±4 - - 143±5 141±7 146±3 142.3±5 - - - - - -
K+ [mEq/L] 4.2±0.3 3.6±0.2* - - 4.3±0.3 3.9±0.4 4.2±0.2 3.9±0.6 - - - - - -
Cl- [mEq/L] 106±6 90±8* - - 94±5 81±4* 82±3 72±4* - - - - - -
Phosphate 




7.0±0.5 7.3±1.0 - - 1.1±0.6 1.6±0.7* 0.9±0.4 1.3±0.9 - - - - - -
Magnesium 
[mg/dL] 1.2±0.1 1.1±0.1* - - 0.7±0.1 0.7±0.1 0.6±0.1 0.6±0.2 - - - - - -
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Table E5.   Plasma laboratory biochemistry exams before and after induction of 
metabolic lactic acidosis.
* p<0.05 vs baseline step in treatment group; ‡ p<0.05 vs baseline step in control group. p-value of difference between groups 
with a 2-way ANOVA for repeated measurements. AST=Aspartate-Aminotransferase; IU=international unit; ALT=alanine amino-
transferase; Gamma-GT=Gamma-Glutamyl-Transferase; LDH=Lactate Dehydrogenase; Hb=hemoglobin.
CRe-ED treatment Observation
Baseline






















[mg/dL] 96±16 96±37 158±53* 152±26 158±18* 200±39‡ 148±17 190 ± 92‡ 0.279
AST [IU/L] 37±11 46±25 29±8 39±11 27±9 38±6 28±10 29 ± 10‡ 0.240
ALT [IU/L] 36±7 45±7 36±6 45±6 36±8 45±6 36±5 46 ± 5 0.047
Gamma-GT [IU/L] 36±23 19±5 23±6* 16±3 24±8* 15±4 22±4* 17 ± 4 0.091
Total Bilirubin 
[mg/dL] 0.06±0.02 0.11±0.09 0.04±0.02 0.05±0.01 0.07±0.07 0.11±0.11 0.07±0.08 0.06 ± 0.03 0.257
Albumin [g/dL] 2.5±0.5 2.6±0.5 2.4±0.4 2.5±0.5 2.4±0.5 2.4±0.5 2.3±0.4 2.4 ± 0.5 0.828
Phosphate 
[mg/dL] 8.5±1.4 10.4±1.5 7.3±1.0 9.6±2.4 6.6±0.7 7.9±1.3 7.7±1.2 8.9 ± 1.9 0.453
Total Calcium 
[mg/dL] 10.0±0.4 10.0±0.6 10.9±0.7 11.0±0.8 10.1±0.6 10.4±0.2 9.9±0.7 9.9 ± 0.3 0.447
Magnesium 
[mg/dL] 1.8±0.1 2.1±0.4 1.8±0.1 2.1±0.4 1.4±0.2* 1.9±0.2 1.7±0.3 2.0 ± 0.3 0.024
LDH [IU/L] 507±86 699±248 485±85 640±188 494±89 626±153 480±75 611 ± 123‡ 0.108
Hb [g/dL] 7.1±0.9 7.4±1.0 7.1±0.9 7.2±1.2 7.1±0.8 7.2±1.7 6.3±1.0* 6.6 ± 1.6 0.761
Platelets [109/L] 221±147 262±46 209±136 271±55 190±110 231±54 122±94* 178 ± 53‡ 0.510
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Table E6. Respiratory variables before and after induction of metabolic lactic acidosis/
CRe-ED treatment Observation
Baseline





















T°C 36.8±1.4 37.2±0.6 37.4±1.3 37.3±0.2 37.5±1.0 37.3±0.2 37.6±1.2* 37.5±0.5 0.972
PEEP, 
cmH2O
5±1 6±3 4±1 6±3 4±1 6±1 5±1 7±3 0.181
FiO2, % 47±5 48±5 47±5 48±5 47±5 48±5 47±5 48±5 0.807
PaO2, 
mmHg 191±39 188±43 165±20 181±49 203±21 177±55 189±34 164±42 0.632
MAP, 
cmH2O












2.1±0.4 2.3±0.2 3.2±0.7* 3.4±0.6‡ 3.1±0.6* 3.7±0.6‡ 3.3±0.9* 3.9±0.7‡ 0.298
* p<0.05 vs baseline step in treatment group; ‡ p<0.05 vs baseline step in control group. p-value of difference between groups with a 2-way ANOVA for repeated measurements. p-value of group-by-
time interaction with a 2-way ANOVA for repeated measurements. FiO2=inspiratory fraction of oxygen; MAP=mean airway pressure; PEEP=positive end expiratory pressure.
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Table E7. Change of pH, pCO2 and electrolytes at the end of CRe-ED treatment in the 
blood pre-filter and blood-post-filter withdrawal port along the extracorporeal circuit 
after induction of metabolic acidosis. 
1-blood pre-filter 2-blood post-filter












pH 7.18±0.05 7.27±0.09* 7.23±0.07 7.29±0.09*
pCO2 [mmHg] 62.2±8.6 68.4±13.2 70.2±11.6 78.2±15.8*
pO2 [mmHg] 42.7±5.1 37.4±3.5 41.9±5.2 36.8±3.1
FiO2 40±3 41±3 40±3 41±3
HCO3- [mEq/L] 22.6±3.4 30.2±4.4* 28.0±4.1 36.6±6.7*
Lactate [mEq/L] 13.6±1.6 14.0±1.4 13.1±1.8 13.4±1.7
Na+ [mEq/L] 137±3 136±2 137±3 136±3
K+ [mEq/L] 3.3±0.4 3.1±0.5* 3.3±0.4 3.1±0.5
Cl- [mEq/L] 99±4 89±5* 95±4 85±7*
Ca++ (mmol/L) 1.5±0.1 1.3±0.1* 1.2±0.2 1.1±0.2
Total Calcium 
[mg/dL] 10.9±0.5 10.4±0.6* 9.8±1.9 9.1±1.6
Phosphate 
[mg/dL] 6.9±0.8 6.7±0.7 6.2±0.9 6.0±0.9
Magnesium 
[mg/dL] 1.7±0.1 1.4±0.2* 1.5±0.2 1.3±0.2*
* p < 0.05 vs 1 hour ED treatment same withdrawal port by paired t-test.
Electrolytes were all measured by gas analyses (ABL 800 gas analyzer; Radiometer), except for total Calcium, phosphate and 
magnesium that were measured by laboratory testing (ADVIA Chemistry, Siemens).
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Table E8. Change of pH and electrolytes at the end of CRe-ED treatment in the different withdrawal ports along the 
extracorporeal circuit after induction of metabolic acidosis.
* p < 0.05 vs 1 hour ED treatment same withdrawal port by paired t-test.
PH of all fluids were measured with a dedicated pH-meter (HI9026, Hanna Instruments), while electrolytes were all measured by laboratory testing (ADVIA Chemistry, Siemens).
3 ultrafiltrated fluid
4 ED base inlet 
pre-filter
5 ED base inlet 
post-filter
6 ED base outlet 
pre-ML
7 ED base outlet 
post-ML












































pH 7.39±0.21 7.48±0.25 10.90±0.29 10.46±0.18* 10.81±0.14 10.47±0.24* 12.43±0.22 12.25±0.30 7.96±0.20 7.85±0.22 5.18±1.84 6.36 ± 1.94 1.39 ± 0.97 1.82 ± 1.46
Na+ [mEq/L] 144±3 147±6 - - 144±3 144±2 145±4 143±3 - - - - - -
K+ [mEq/L] 3.8±0.8 3.3±0.7 - - 3.8±0.6 3.4±0.8* 3.4±0.3 3.3±0.6 - - - - - -
Cl- [mEq/L] 103±4 91±10* - - 91±3 84±4* 78±3 72±4* - - - - - -
Phosphate 




8.4±0.5 6.9±3.2 - - 0.7±0.2 1.0±0.2* 0.7±0.1 1.3±0.8 - - - - - -
Magnesium 
[mg/dL] 1.3±0.1 1.1±0.3 - - 0.6±0.1 0.6±0,1 0.6±0.1 0.7±0.1 - - - - - -
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